Antimicrobial Resistance Surveillance Market

The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period . The growth in this market is driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, escalating threat of antimicrobial resistance, growing government initiatives to combat antimicrobial-resistance species, and emergence of multi-drug resistance due to drug abuse. On the other hand, factors such as high cost of antimicrobial resistance diagnostic systems/ kits are limiting the growth of this market.

The prominent players in this market are Luminex Corporation (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Qiagen (Germany), Lumed (US), Becton, Dickinson and Company (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Wolters Kluwer N.V. (US), Abbott Laboratories (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Danaher (US), Bioanalyse (Turkey), Biomerieux (France), Thermo Fisher Scientific (US), and Alifax S.r.l. (Italy).

To know about the assumptions considered for the study download the pdf brochure

BioMerieux (France) BioMérieux specializes in providing in vitro diagnostic solutions that determine the source of a disease or contamination to improve patient health and ensure consumer safety. The company’s products are mainly used in the clinical field for diagnosing infectious diseases and in the industrial field for the detection of microorganisms in agri-food and pharmaceutical and cosmetic products. The company has five business segments, namely, immunoassays, molecular biology, industry, other ranges, and microbiology. The antimicrobial resistance surveillance products were offered through microbiology segment.

It invests in R&D and offers a wide range of antimicrobial resistance surveillance solutions. A part of the company’s R&D activities is based on partnership arrangements with leading public research institutes, universities, hospital research centers, laboratories, and biotechnology firms. BioMérieux has a wide geographic presence in more than 150 countries across the Americas, Europe, the Middle East & Africa, and the Asia Pacific.

Becton, Dickinson, and Company (US) is a leading global medical technology company dedicated to the research, development, manufacturing, and distribution of a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Their comprehensive portfolio caters to the needs of healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the public and are committed to delivering innovative solutions that enhance healthcare outcomes and improve the quality of patient care.

BD’s operations consist of three worldwide business segments—BD Medical, BD Life Sciences, and BD Interventional. The antimicrobial resistance surveillance products are offered through BD Life Sciences segment. The BD Lifesciences segment is further divided into Integrated diagnostic solutions, and Biosciences. BD provides customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications. BD’s products are marketed and distributed in the US and internationally through independent distribution channels, as well as directly to hospitals and other healthcare related institutions by BD and independent sales representatives.

Thermo Fisher Scientific (US) Thermo Fisher Scientific was founded through the merger of Thermo Electron and Fisher Scientific. The company offers a complete and integrated portfolio of solutions and services for clinical science and laboratory research and analysis. The company operates through four broad segments, namely, Analytical Instruments, Specialty Diagnostics, Life Science Solutions, and Laboratory Products and Biopharma Services. The microbiology business under the company’s Specialty Diagnostics segment offers dehydrated and prepared culture media, collection and transport systems, microbiology instrumentation, and consumables to detect pathogens in blood, diagnostic, and rapid direct specimen tests, quality-control products, and associated products for antimicrobial resistance.

It has a strong geographic presence across the US, China, Germany, and the UK. Some of the company’s notable subsidiaries are Thermo Electron Australia Pty Limited (Australia), Thermo Informatics Asia, Pty Ltd. (Australia), Thermo Electron Holdings SAS (France), Thermo Fisher Scientific C.V. (Netherlands), Thermo Finland Holdings LLC (US), Thermo Electron India Private Limited (India), Thermo Fisher Scientific (China) Holding Limited, Thermo Life Science International Trading (Tianjin) Co., Ltd. (China), Thermo Fisher Scientific K.K. (Japan), Thermo BioAnalysis LLC (US), Thermo Fisher Scientific Oy (UK), Thermo CRS Holdings Ltd. (Canada), and Thermo NITON Analyzers LLC (US).

Related Reports:

Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]